AR and neoplasm: Schwartz and co-workers showed that inhibiting multiple PI3K isoforms leads to greater tumor mass reduction compared to dual drug treatment targeting AR and predominantly on PI3K isoform.15 In this context, our data suggests that 14-3-3 protein isoforms are plausible new target for combinational therapy in PCa.